New drug KESONOTIDE™ enters human trials for multiple cancers

NCT ID NCT06926075

First seen Oct 01, 2025 · Last updated May 16, 2026 · Updated 20 times

Summary

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, pancreatic, skin cancer, or glioblastoma. The main goal is to check if the drug is safe and tolerable, and to find the right dose. About 80 adults will take part in two phases, starting with a small group to test safety, then expanding to more participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • South Western Sydney Local Health District

    RECRUITING

    Liverpool, New South Wales, 2170, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Southside Cancer Centre

    RECRUITING

    Miranda, New South Wales, 2228, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • St George Private Hospital

    RECRUITING

    Kogarah, New South Wales, 2217, Australia

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.